Interesting company here: CB7630 appears to have significant anti-tumor activity in chemotherapy-naive patients with castration-refractory prostate cancer despite hormonal therapy.
The only thing is that--since Yahoo doesn't provide market caps for bulletin board stocks--I calculated that this thing has a market cap of at least $440 million. Or am I miscalculating? Seems a little rich for a company with one drug in phase II and a couple in phase I.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.